Any substance use disorder according to DSM-IV criteria Mental and Behavioural Disorders Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances
Conditions
Interventions
Study Intervention:
Three individual behavioral therapy sesisons of Motivational Enhancement Treatment delivered weekly during the first 28 days of treatment + regular concurrent interventions for sub
Sponsors
U.S. Department of State (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female between 18 and 65 years old 2. Requesting ambulatory treatment for substance abuse 3. Reporting any substance use at least within 28 days before treatment 4. Willing to be assigned randomly to one of the intervention groups 5. Being available in the area where the study would be held, at least, during the four months of study duration 6. Having a stable home address where they can be contacted within the duration of the study 7. Reporting to have understood the conditions of the study and give their informed consent
Exclusion criteria
Exclusion criteria: 1. Presenting medical conditions and psychiatric instability that excludes the possibility of receiving ambulatory treatment. Therefore, those who present cognitive deterioration or other organic-brain damage, uncontrolled psychotic symptoms, suicidal ideation or suicidal or homicidal behaviors when starting treatment, is not considered eligible to participate in the study. 2. Being in a legal situation that involves the possibility of imprisonment or visits to an entity of the judicial system during the four months following admission to treatment 3. Women in the eighth month of pregnancy or past the eighth month, whose state of birth and/or postpartum period may interfere with their participation in the study 4. Requesting only detoxification treatment 5. Requesting opiate substitution treatment with methadone or buprenorphine 6. Having a couple, husband or significant other (e. g. family with those who share housing) who is participating in this research protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. For Substance Use: Days of substance use reported using a scheduled self-report assessment (Time Line Follow-Back) and drug or alcohol presence measured using qualitative measures for urine and breath samples. These will be measured at baseline, three times during treatment and at follow-up. 2. For Treatment Retention: Self-report of treatment utilization and involvement during the treatment phase and at follow-up. We contemplated three follow-up assessments: one post-treatment assessment at the end of the 28-day treatment phase, a first follow-up assessment at 8 weeks after randomization (Follow-Up 1) and a second follow-up (Follow-up 2) 16 weeks after randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Participant individual characteristics such as motivation for change, HIV risk behavior, therapeutic alliance, substance use-related problems and treatment expectations and satisfaction is measured at baseline, at the end of the 28 day treatment phase, and at two follow-ups on 8 and 16 weeks after randomization 2. For therapeutic process, treatment discriminability assessment and fidelity to the MET intervention, audio-recordings of all treatment sessions delivered during the 28-day treatment phase are listened and evaluated by an independent rater who is blinded to their treatment condition at no specific time-point | — |
Countries
Mexico
Outcome results
None listed